Objective: To determine the impact of delayed treatment of methicillin-resistant Staphylococcus aureus bacteraemia (MRSA bacteraemia) on mortality.
Introduction
Staphylococcus aureus is a major cause of hospital-acquired infections. Hospitals worldwide are faced with increasingly rapid emergence and spread of antibiotic-resistant Staphylococcus aureus. Methicillin-resistant S. aureus (MRSA) infections are increasing, and many physicians have difficulty in deciding whether vancomycin or other glycopeptides should be included in empirical antibiotic regimens until preliminary microbiology reports are available.
Several reports have noted that appropriate empirical antibiotic treatment had a favourable effect on outcome in S. aureus bacteraemia. [1] [2] [3] Others reported that inappropriate empirical treatment did not result in a significant difference in outcome. [4] [5] [6] Therefore, it is uncertain whether an initial delay in the use of appropriate antibiotic treatment of MRSA bacteraemia adversely affects the outcome. We performed this study to evaluate the effect of inappropriate empirical antibiotic treatment on the outcome of patients with MRSA bacteraemia, using two different and complementary approaches: a retrospective cohort study and a matched case -control study.
Patients and methods

Study population
Seoul National University Hospital is a university-affiliated tertiary hospital with 1500 beds. The hospital provides specialized medical and surgical care, including bone marrow and solid organ transplantation for adult (>15 years of age) patients.
All patients with blood cultures positive for S. aureus were identified from a retrospective review of the computerized records of the Clinical Microbiology Laboratory between 1 January 1998 -31 October 2001. Only the first clinically significant episode of S. aureus bacteraemia for each patient was included in the analysis. Patients who had S. aureus bacteraemia as part of a polymicrobial bloodstream infection were excluded.
Microbiological tests
Identification of S. aureus was carried out with VITEK GPI Cards (bioMérieux, Hazelwood, MO, USA). Antibiotic susceptibilities were determined using the disc diffusion method, following the recommendations of the National Committee for Clinical Laboratory Standards. 7 
Study design
The first part was a retrospective cohort study of 127 cases of MRSA bacteraemia from a total with S. aureus bacteraemia. The outcome of 30 patients with appropriate empirical antibiotic treatment was compared with 97 patients with inappropriate empirical antibiotic treatment. The second part was a matched (1:1) case -control study. For the purpose of this study, the patients with MRSA bacteraemia treated with an appropriate empirical antibiotic regimen are designated as 'cases' and those with MRSA bacteraemia treated with an inappropriate empirical antibiotic regimen as 'controls'.
Definitions
Definition of terms. S. aureus bacteraemia was classified as community-acquired if the organism was isolated from blood cultures drawn within 72 h of admission, if the patient was not transferred from another hospital and had suggestive symptoms or signs of infection on admission. 8 Community-acquired MRSA bacteraemia was further classified into healthcare-associated infection if the patient had been exposed recently to a healthcare setting (i.e. had attended a hospital or haemodialysis clinic, or had resided in a long-term care facility). 9 Hospital-acquired MRSA bacteraemia was defined by a positive blood culture obtained from patients who had been hospitalized for 72 h or longer.
Previous antibiotic use was defined as a patient who had been treated with any antimicrobial agent for more than 7 days during the month before the S. aureus bacteraemia. 3 Previous surgery was defined as a patient who had had an operation within the month before the S. aureus bacteraemia. 3 A history of MRSA colonization was defined as a case in which MRSA was isolated from any specimens (i.e. sputum, wound and urine) within the preceding 6 months before the S. aureus bacteraemia. A hospital stay was defined as the length of hospital stay from the time of admission to the occurrence of S. aureus bacteraemia.
Foci of bloodstream infection. The primary foci of infection were determined using the following definitions. Catheter-related infection was considered as the source of bacteraemia, 10 if: (i) the culture of a specimen of purulent drainage from the insertion site grew S. aureus that had the same resistance pattern as the culture strain from the peripheral blood, or the clinical signs improved within 2-3 days after the catheter had been removed, and (ii) no other source for bacteraemia existed. We used such indirect clinical evidence of catheter-related infection in the absence of laboratory confirmation of catheter-related infection (i.e. quantitative culture of blood or semi-quantitative culture of a catheter segment, which was not conducted in our hospital during the study period). Pneumonia was considered as the source of S. aureus bacteraemia if: (i) the patient had clinical symptoms and signs of a lower respiratory tract infection, and (ii) there was radiological evidence of pulmonary infiltrates not attributable to other causes. 8 Soft tissue infection was considered as the source of S. aureus bacteraemia in cases where patients: (i) had a culture of S. aureus from a tissue or a drainage specimen from the affected site and (ii) had signs of infection. 8 Surgical wound infection was defined according to the definitions of the Centers for Disease Control and Prevention. 11 Infective endocarditis was defined using the modified Duke criteria. 12 If a primary focus of infection could not be determined, it was considered to be unknown.
Antibiotic treatment and outcome. Decisions regarding empirical antibiotic regimens were the responsibility of the primary care physicians. The empirical antibiotic treatment was considered appropriate if the empirical therapy given intravenously within the first 48 h from the onset of the bacteraemia included at least one antibiotic to which the isolate was susceptible. 4, 5, 13 In our institution, vancomycin has been administered intermittently; none of our patients-among either the appropriate or inappropriate empirical treatment groups-received vancomycin via continuous infusion.
The treatment outcomes of S. aureus bacteraemia were assessed at 12 weeks after the onset of S. aureus bacteraemia, according to the following criteria: cure (resolution of clinical signs of infection during therapy and no evidence of recurrent S. aureus bacteraemia within 12 weeks of follow-up), recurrence (clinical resolution of signs and symptoms of infection during therapy, but recurrent S. aureus bacteraemia within 12 weeks of follow-up), non-S. aureus bacteraemia-related mortality (death due to underlying diseases or another process, with no evidence of S. aureus infection at the time of death), and S. aureus bacteraemia-related mortality (death occurring before the resolution of symptoms or signs or within 7 days from the onset of S. aureus bacteraemia and if there was no other explanation). 3, 14 Matching process. Each patient with appropriate empirical treatment (case patient) was matched with a patient with inappropriate empirical treatment (control patient) who was selected according to age, sex, the McCabe and Jackson classification of severity of underlying illness (classified as rapidly fatal when death was expected within a period of days or weeks, ultimately fatal when death was expected within a period of months or years, and non-fatal when death was not expected), 3, 15, 16 the same main underlying disease and length of hospital stay before S. aureus bacteraemia (stratified into four categories: <72 h, 3-7, 8-28 and >28 days). 3, 8 To select the best control for each case patient, we used a 14-point scoring system based on the above-listed matching variables, similar to that described elsewhere: 8, 17 ,18 matching for age (three points if age difference ±< _ 5 years, two points if age difference ±6 -10 years, no point if age difference ±>10 years); matching for sex (two points in cases of concordance, no point if discordant matching); matching for the same McCabe and Jackson classification of severity of illness-rapidly fatal, ultimately fatal and non-fatal (three points for concordance, no point in cases of discordance); matching for the same main underlying disease, such as cardiovascular disease, haematological malignancy, solid tumour, liver cirrhosis, end-stage renal disease, rheumatological disease, other diseases and no disease (three points for concordance, no point in cases of discordance); and matching for the same length of hospital stay before S. aureus bacteraemia (three points if in the same category as mentioned above, no points if not). The best control patient was selected on a subject-to-subject basis using the above score system. If several control patients had the same point score, one of them was selected at random. Control patients were chosen without the knowledge of the case patients' survival status.
Statistical analysis
The results were analysed using the SPSS version 10.0 for Windows software package (SPSS Inc, Chicago, IL, USA). The categorical variables were compared by Fisher's exact tests or Pearson x 2 tests, as appropriate, and the continuous variables were compared by Mann-Whitney U-test or Student t-tests. The McNemar's test with continuity correction was performed to test the comparison of mortality for the case and control patients. All tests of significance were two-tailed; P values < _ 0.05 were considered significant. Independent predictors for S. aureus bacteraemia-related mortality in the cohort study were identified by means of backward stepwise logistic regression analysis, with a limit of removing variables with a P value >0.10 from the equation. Survival curves for patients with appropriate and inappropriate empirical treatment were prepared according to the Kaplan -Meier method. The log-rank test was used to determine significance between survival curves.
Results
Cohort study
During the study period, 127 patients with MRSA bacteraemia were identified. Eight patients were classified as having community-acquired infection, but all had been recently exposed to a healthcare setting. Thirty (24%) of 127 patients with MRSA bacteraemia were treated with an appropriate empirical antibiotic regimen. Of 127 MRSA bacteraemic patients, 57 (45%) were cured and four (3%) recurred. The overall death rate-non-S. aureus bacteraemia-related death and S. aureus bacteraemiarelated death at 12 weeks after the onset of S. aureus bacteraemia-was 52% (66/127), 15% (19/127) and 37% (47/127), respectively. Of 47 patients with S. aureus bacteraemia-related deaths, 15 (32%) deaths occurred within 4 days of obtaining a blood sample for culture and 39 (83%) within 14 days ( Figure 1 ). The mean time (±S.D.) from the onset of bacteraemia to S. aureus bacteraemia-related death was 9.1±7.6 days (range 1-30 days).
The schematic flowchart for appropriate and inappropriate empirical treatment is shown in Figure 2 . In all 30 MRSA bacteraemic patients with an appropriate empirical antibiotic regimen, vancomycin (n = 28) or teicoplanin (n = 2) was used as an empirical antibiotic treatment and was given with adequate usual dosage within 2 days from the onset of S. aureus bacteraemia. Of these 30 patients, 28 were initially given vancomycin or teicoplanin at the onset of S. aureus bacteraemia, and two were initially given inappropriate empirical antibiotics (in vitro not susceptible antibiotics) but switched to vancomycin within 1 day from the onset of S. aureus bacteraemia because the preliminary blood culture results with Gram staining findings were available as early as 24 h from the onset of S. aureus bacteraemia. Consequently, these two patients were classified into the appropriate empirical treatment group. Of 97 MRSA bacteraemic patients receiving inappropriate empirical antibiotic treatment, Figure 1 . Distribution of 47 S. aureus-related deaths from the time initial blood cultures were obtained. A total of 83% of the deaths occurred within 14 days after a blood sample was obtained for culture.
77 patients (80%) were given b-lactam ± aminoglycoside (to which the isolated strains were resistant) as empirical antibiotic treatment within 2 days from the onset of S. aureus bacteraemia. A further eight (8%) were given quinolone ± aminoglycoside, six (6%) b-lactam ± quinolone, and six (6%) no parenteral antibiotics. No patients received co-trimoxazole, linezolid or quinupristin/dalfopristin as empirical antibiotic treatment. Of 117 patients who received definite treatment with appropriate antibiotics (excluding 10 patients who never received appropriate antibiotics), 108 patients received vancomycin, three teicoplanin, five vancomycin combined with aminoglycoside and one vancomycin combined with aminoglycoside and rifampicin. Definite antibiotic treatments (i.e. antibiotics after the susceptibility results) were not different between inappropriate and appropriate empirical treatment groups.
The clinical characteristics of MRSA bacteraemic patients receiving appropriate empirical antibiotic regimen and those receiving inappropriate empirical antibiotic regimen are shown in Table 1 . Results of univariate analysis of the association of possible risk factors with S. aureus bacteraemia-related mortality showed that severity of underlying disease, such as ultimately or rapidly fatal illness (OR 8.5, 95% CI 1.9-38.2), primary site of infection, such as unknown primary site (OR 7.6, 95% CI 3.4 -17.3) and underlying liver cirrhosis (OR 3.8, 95% CI 1.3-11.0) were associated with poor outcome. In contrast, primary site of infection, such as catheter-related infection (OR 0.1, 95% CI 0.03-0.36) was associated with good outcome. However, inappropriate empirical antibiotic treatment was not associated with mortality (OR 1.5, 95% CI 0.6-3.6). Of 29 patients who experienced S. aureus bacteraemia in the intensive care unit setting, the difference in S. aureus bacteraemia mortality between appropriate [30% (3/10)] and inappropriate empirical therapy [37% (7/19)] was not statistically significant (P = 0.99). A multivariate analysis using the logistic regression model is shown in Table 2 .
In subgroups excluding those patients (n = 10) who never received appropriate antibiotic therapy or those patients (n = 15) who died before the results of blood culture were available (Figure 2) , the difference in S. aureus bacteraemia-related mortality between inappropriate empirical treatment [32% (28/87) or 31% (26/85), respectively] and appropriate empirical treatment [30% (9/30) or 22% (6/27), respectively] was not significant (P = 0.82 and P = 0.40, respectively). The difference in S. aureus bacteraemia-related mortality prior to the microbiological reports between inappropriate (12%, 12/97) and appropriate empirical treatment (10%, 3/30) was not significant (P = 0.99, Figure 2 ).
Matched case -control study
There were 30 pairs of case and control patients who were matched for age, sex, the McCabe and Jackson classification of severity of underlying illness, main underlying disease and the length of hospital stay. The average age was 55 years in case and 56 years in control, respectively. Of 30 case -control pairs, 23 (77%) were successfully matched for sex, 28 (93%) for the same McCabe and Jackson classification of severity of illness, 22 (73%) for the same main underlying disease and 19 (63%) for the length of hospital stay before S. aureus bacteraemia (concordance in the same categories mentioned above). The details of the results of matching are shown in Table 3 . Overall, on the 14-point matching scale, the 30 controls had an average score of 11.2 points (S.D. 2.0, range [8] [9] [10] [11] [12] [13] [14] .
Baseline clinical characteristics and outcomes are shown in Table 4 . The time to defervescence in the inappropriate empirical treatment group (median 7.0 days) was longer than that in the appropriate empirical treatment group (median 3.5 days), but this difference was not statistically significant (P = 0.15).
S. aureus bacteraemia-related mortality was 30% in case patients and 33% in control patients (P > 0.99, McNemar's test). Twenty-one matched pairs had a concordant outcome (16 pairs lived and five died). Nine pairs had a discordant outcome; in four of these the case-patient died and the control-patient lived, and in five the case-patient lived and the control-patient died ( Table 5 ). The survival curves in the matched case-control study, stratified according to appropriateness of empirical treatment, are presented in Figure 3 .
In the subgroups excluding patients (n = 2) who never received appropriate effective therapy (i.e. vancomycin or teicoplanin) or patients (n = 5) who died before the results of blood cultures were available, the difference in S. aureus bacteraemiarelated mortality between inappropriate empirical treatment [29% (8/28) or 29% (8/28), respectively] and appropriate empirical treatment [30% (9/30) or 22% (6/27), respectively] was not significant (P = 0.91 and P = 0.59, respectively). We compared the S. aureus bacteraemia-related mortality among the 25 matched pairs excluding the five matched pairs who never received appropriate therapy or who died prior to the microbiologic report. S. aureus bacteraemia-related mortality was 24% (6/25) in case patients and 24% (6/25) in control patients (P = 0.68, McNemar's test). Nineteen matched pairs had a concordant outcome (16 lived and three died). Six pairs had a discordant outcome; in three of these the case-patient died and the control-patient lived.
Discussion
The empirical antibiotic regimen should be individualized according to a given institution's antibiotic resistance pattern and clinical setting. However, with some cases, MRSA infections are not initially suspected because clues for S. aureus infection are lacking, and preliminary microbiological results, including antibiotic susceptibility, are usually unavailable for the first 2 days. Several studies have demonstrated that the initial delay of appropriate antibiotic treatment could have an adverse affect on the outcome, especially in Gram-negative bacteraemia, 19 intensive care units settings 20 -22 and ventilator-associated pneumonia. 23 However, there are conflicting data regarding the outcome of an initial delay of appropriate antibiotic treatment a Data are presented as the number (%) of patients unless indicated otherwise. b All eight patients were recently exposed to a healthcare setting, so all the cases were healthcare-associated infections.
for S. aureus bacteraemia. [1] [2] [3] [4] [5] [6] In most studies, inappropriate empirical antibiotic treatment was more closely correlated with MRSA bacteraemia than with methicillin-susceptible S. aureus (MSSA) bacteraemia. However, patients with MRSA bacteraemia are more likely than patients with MSSA bacteraemia to have serious underlying disease and prolonged hospitalization. 3 Therefore, the severity of underlying disease may distort the comparison of outcomes between inappropriate and appropriate empirical antibiotic treatment.
Previous studies showing an association of inappropriate empirical treatment with mortality may have overestimated the efficacy of the empirical antibiotic treatment due to inadequate adjustment for underlying disease or severity of clinical condition. A good example may be found in a previous report, 13 where we demonstrated that the difference in S. aureus bacteraemia-related mortality between inappropriate and appropriate empirical treatment was not significant in patients with eradicable foci of S. aureus bacteraemia (OR 1.2, 95% CI 0.4-4.3, P = 0.78). However, inappropriate empirical treatment affected the outcome adversely in patients with non-eradicable foci of S. aureus bacteraemia (OR 2.1, 95% CI 1.1-4.2, P = 0.03). Since methicillin resistance was closely correlated with inappropriate empirical treatment, the logistic regression model did not reveal that inappropriate empirical therapy was associated with mortality in this subgroup after adjustment for methicillin resistance.
A recent meta-analysis showed that MRSA bacteraemia was associated with significantly higher mortality than MSSA bacteraemia. 24 This was true both if all-cause mortality and S. aureus bacteraemia-related mortality were evaluated. Hence, methicillin resistance itself may confound the association of inappropriate empirical treatment with mortality. Therefore, we included only patients with MRSA bacteraemia in the cohort study in order to evaluate the impact of empirical antibiotic treatment on mortality without the influence of methicillin resistance. Univariate and multivariate analysis in our cohort study did not show any association of initial delay in appropriate antibiotic treatment with mortality of patients with MRSA bacteraemia (OR 1.5, 95% CI 0.6-3.6; adjusted OR 1.1, 95% CI 0.4 -3.1). In addition, after patients with inappropriate and appropriate empirical antibiotic treatment were carefully matched, the impact of an initial delay of appropriate antibiotic treatment on outcome remained marginal (attributable S. aureus bacteraemia-related mortality 3.3%, 95% CI À20.2%-26.9%). A possible explanation for these results is that most Gram-positive pathogens are usually not rapidly lethal. 25 That is, the infection progresses rapidly to fatal sepsis in only a minority of patients with MRSA bacteraemia, and an initial delay in appropriate treatment might not necessarily lead to a worse outcome. 4 This hypothesis is supported by many clinical studies with neutropenic cancer patients. 26 -28 We believe that the initial antibiotic choice seldom, if ever, influences the fate of rapidly fatal outcomes of S. aureus bacteraemia. The hypothesis that there is a physiological 'point of no return' prior to antibiotic therapy has been confirmed in pneumococcal bacteraemia 29, 30 and sepsis of critically ill patients.
31
There is a growing concern about community-acquired MRSA. 32 No case of true community-acquired MRSA bacteraemia was included in this study, but it is an interesting issue whether inappropriate empirical treatment in recently emerged virulent community-acquired MRSA infection may adversely affect the outcome. Non-glycopeptide anti-staphylococcal antibiotics, such as co-trimoxazole, quinupristin/dalfopristin and linezolid, were not used as empirical therapy in this study but may have a favourable effect if used empirically. In addition, vancomycin-intermediate resistant S. aureus or heterogeneous vancomycin-intermediate resistant S. aureus strains might be a confounding factor, although none of our MRSA isolates showed reduced susceptibility to vancomycin. 33 Some may consider that a simple measurement of mortality is too crude a way to measure the differences between two groups. Although we did not detect any significant differences in endocarditis or metastatic infection, we could not rule out occult endocarditis or metastatic infection because it was, in the retrospective nature of this study, difficult to assess these complications. However, observational prospective studies on an effect of the adequacy of initial empirical antimicrobial treatment on outcome are not easy to conduct because awareness of the ongoing study might influence medical prescription. 34 One may argue that a certain proportion of patients who were classified into the inappropriate empirical treatment group might receive adequate partial treatment (i.e. an aminoglycoside). Almost all MRSA strains isolated in our hospital were resistant to aminoglycosides. 35 All patients who were classified as inappropriate empirical therapy received other antibiotics to which the isolates were resistant in vitro.
The inclusion of patients who died in the first 4 days, when antibiotics are unlikely to have an effect on outcome, and any patient who never received appropriate antibiotics would seem to dilute our results. Thus, we compared the outcome of two subgroups, excluding patients with rapidly fatal outcomes or those treated without susceptible antibiotics in the cohort study and matched case-control study. These analyses revealed similar results.
The results of the cohort study showed a 9% difference in mortality between inappropriate and appropriate empirical antibiotic treatment, although this did not reach statistical significance. However, it is possible that our sample size was too small to achieve statistical significance. The relatively wide confidence interval also suggested this possibility. Indeed, the statistical power was 15% in the cohort study. The study should include more than 870 patients (435 in each group) to detect this statistically significant difference with a 5% bilateral alpha and a power of 80%. Because of this limitation, we used the complementary approach in a matched case -control study. We believed that consistency (similar marginal elevation of risk) in two different analytic approaches would support our results. Furthermore, the subgroup analyses to exclude the cases that could dilute our results revealed similar results. However, this matching analysis and subgroup analyses could not control for a detection bias due to a limited power of our study.
In addition, some might criticize an atypical method of performing a case -control study. 36 However, we believe that if there had been any intrinsic association of the appropriateness of a Data are presented as the number (%) of patients unless indicated otherwise. b This patient was recently exposed to a healthcare setting, so this case was healthcare-associated infection. c P = 0.01 (none of the variables differed significantly between the two groups except the previous MRSA colonization).
empirical treatment with S. aureus bacteraemia-related mortality, the measure of association (OR) could have been presented in this study design, regardless of their sequence in real time. 36 In fact, this study design should be considered a matched cohort study. The efficacy and appropriateness of matching in cohort studies remains to be evaluated. 37 Several studies demonstrated the usefulness of a matched cohort study with a design similar to ours. 3, 8, 17, 18, 38, 39 The use of a tertiary hospital cohort and the high mortality rate because of the inclusion of patients with rapid fatality and severe underlying diseases does, nevertheless, limit the extent to which our findings can be generalized. Another limitation was that we did not attempt to determine the factors influencing the delay in the attending physicians' use of appropriate antibiotic treatment. Hence we cannot rule out the possibility that any unmeasured confounding factor might affect our results. Finally, this was an observational study, not one designed to prove causality between appropriate empirical regimen and outcome; a randomized, controlled trial would provide more valid data. However, as prospective clinical trials are neither feasible nor ethical, alternative study designs, such as the one used in our study, are often needed to answer important policy questions.
The alternative strategy to glycopeptide restriction before the culture results are available is to include vancomycin in all empirical antibiotic regimens. This strategy inevitably results in unnecessary use of vancomycin and the possible emergence of vancomycin-resistant organisms. A good option for prudent glycopeptide use is to give glycopeptides to patients with risk factors for MRSA infection, and to optimize the therapy when microbiological data are provided. However, one major problem of this approach is that most patients with hospital infection receive empirical glycopeptides if MRSA is endemic in the institution. Indeed, MRSA is becoming endemic in more institutions. Rapid bacterial identification and antimicrobial susceptibility testing may reduce unnecessary glycopeptide use.
In conclusion, our data suggest that an initial delay of 2 days in the use of appropriate antibiotics, especially of vancomycin, prior to a preliminary microbiological report does not adversely affect outcome in patients with MRSA bacteraemia. Therefore, our study supports the view that restriction of glycopeptide application could be warranted when empirical antibiotics are used if a patient is stable, not deteriorating rapidly, and has no known risk factors for MRSA infection. A large prospective study will be required to confirm our findings. 
